Literature DB >> 12651810

Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction.

Nadhipuram V Bhagavan1, Ernest M Lai, Patricia A Rios, Jinsheng Yang, Anna M Ortega-Lopez, Hiroko Shinoda, Stacey A A Honda, Carlos N Rios, Cheryl E Sugiyama, Chung-Eun Ha.   

Abstract

BACKGROUND: Clinical diagnoses were correlated with results of a Co(II)-albumin binding assay in 167 patients treated at an emergency department of a health maintenance organization.
METHODS: Patients were evaluated as being nonischemic or potentially ischemic through standard coronary disease indicators [creatine kinase (CK), CK-MB, cardiac troponin I, and electrocardiographic findings] and were tested by a Co(II)-albumin binding assay. Samples were tested anonymously, and the study was double-blinded. The sensitivity and specificity of this assay for the detection of ischemia were evaluated by ROC curve analysis. Known Co(II) binding sites on albumin were analyzed by N-terminal amino acid sequencing.
RESULTS: The mean absorbance units (ABSU) +/- 2 SD for non-myocardial ischemic and myocardial ischemic individuals measured at 470 nm were 0.43 +/- 0.10 and 0.63 +/- 0.25, respectively (P <0.0001). The area under the ROC curve was 0.95 [95% confidence interval (CI), 0.92-0.99], and at a cutoff value of 0.50 ABSU, sensitivity and specificity were 88% (78-94%) and 94% (86-98%), respectively, suggesting a high distinction between the two groups. When we compared non-acute myocardial infarction (AMI) and AMI ischemic individuals, the area under the ROC curve was 0.66 (95% CI, 0.53-0.79) and was considered a poor discriminator between these two groups. N-Terminal amino acid sequencing data for purified albumin showed normal amino acid residues for six of seven high-ABSU (> or =0.70) individuals and one nonischemic individual tested. However, only one individual with a high ABSU (0.80) had two missing amino acid residues (DA) from the N-terminal region. Clinical diagnosis for this patient did not reveal an ischemic event.
CONCLUSIONS: The Co(II)-albumin binding test may serve as a useful diagnostic tool in emergency facilities for the assessment of myocardial ischemia. High and low ABSU were associated with myocardial ischemic individuals and non-myocardial ischemic individuals, respectively. However, the Co(II)-albumin binding was a poor discriminator between ischemic individuals with and without MI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651810     DOI: 10.1373/49.4.581

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  43 in total

1.  A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]- to human serum albumin.

Authors:  Jihan Talib; Jennifer L Beck; Stephen F Ralph
Journal:  J Biol Inorg Chem       Date:  2006-05-12       Impact factor: 3.358

2.  Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma.

Authors:  M Can; S Demirtas; O Polat; A Yildiz
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

Review 3.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

4.  Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes.

Authors:  C Bhakthavatsala Reddy; Cijo Cyriac; Hrishikesh B Desle
Journal:  Indian Heart J       Date:  2014-12-22

5.  Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels?

Authors:  Aysel Kiyici; Idris Mehmetoğlu; Hatice Karaoğlan; Hüseyin Atalay; Yalçin Solak; Süleyman Türk
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 6.  Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

Authors:  Kazuhiko Kotani; Satoshi Kimura; Alejandro Gugliucci
Journal:  J Physiol Biochem       Date:  2011-04-12       Impact factor: 4.158

7.  Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers.

Authors:  Maria Gabriela Valle Gottlieb; Ivana Beatrice Mânica da Cruz; Marta M F Duarte; Rafael Noal Moresco; Mário Wiehe; Carla Helena Augustin Schwanke; Luiz Carlos Bodanese
Journal:  J Clin Endocrinol Metab       Date:  2009-12-16       Impact factor: 5.958

8.  Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes.

Authors:  Cui Liyan; Zhang Jie; Wu Yonghua; Hu Xiaozhou
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

9.  Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease.

Authors:  Luiz Carlos Cichota; Rafael Noal Moresco; Marta Maria Medeiros Frescura Duarte; José Edson Paz da Silva
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

10.  Estimation of Ischemia Modified Albumin (IMA) Levels in Patients with Acute Coronary Syndrome.

Authors:  Prema Gurumurthy; Sai Krishna Borra; Rama Krishna Reddy Yeruva; Dolice Victor; Sai Babu; K M Cherian
Journal:  Indian J Clin Biochem       Date:  2013-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.